Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A decade of exploring the cancer epigenome - biological and translational implications.

Literature DB >> 21941284

A decade of exploring the cancer epigenome - biological and translational implications.

Abstract

The past decade has highlighted the central role of epigenetic processes in cancer causation, progression and treatment. Next-generation sequencing is providing a window for visualizing the human epigenome and how it is altered in cancer. This view provides many surprises, including linking epigenetic abnormalities to mutations in genes that control DNA methylation, the packaging and the function of DNA in chromatin, and metabolism. Epigenetic alterations are leading candidates for the development of specific markers for cancer detection, diagnosis and prognosis. The enzymatic processes that control the epigenome present new opportunities for deriving therapeutic strategies designed to reverse transcriptional abnormalities that are inherent to the cancer epigenome.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Year: 2011 PMID： 21941284 PMCID： PMC3307543 DOI： 10.1038/nrc3130

Source DB: PubMed Journal: Nat Rev Cancer ISSN： 1474-175X Impact factor: 60.716

162 in total

Review 1. The history of cancer epigenetics.

Authors: Andrew P Feinberg; Benjamin Tycko
Journal: Nat Rev Cancer Date: 2004-02 Impact factor: 60.716

2. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line.

Authors: Einav Nili Gal-Yam; Gerda Egger; Leo Iniguez; Heather Holster; Steingrímur Einarsson; Xinmin Zhang; Joy C Lin; Gangning Liang; Peter A Jones; Amos Tanay
Journal: Proc Natl Acad Sci U S A Date: 2008-08-27 Impact factor: 11.205

3. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

Authors: Steven D Gore; Stephen Baylin; Elizabeth Sugar; Hetty Carraway; Carole B Miller; Michael Carducci; Michael Grever; Oliver Galm; Tianna Dauses; Judith E Karp; Michelle A Rudek; Ming Zhao; B Douglas Smith; Jasper Manning; Anchalee Jiemjit; George Dover; Abbie Mays; James Zwiebel; Anthony Murgo; Li-Jun Weng; James G Herman
Journal: Cancer Res Date: 2006-06-15 Impact factor: 12.701

4. Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations.

Authors: Zeinab Barekati; Ramin Radpour; Corina Kohler; Bei Zhang; Paolo Toniolo; Per Lenner; Qing Lv; Hong Zheng; Xiao Yan Zhong
Journal: Hum Mol Genet Date: 2010-05-12 Impact factor: 6.150

5. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors: Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal: Science Date: 2010-09-08 Impact factor: 47.728

6. DNMT3A mutations in acute myeloid leukemia.

Authors: Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal: N Engl J Med Date: 2010-11-10 Impact factor: 91.245

7. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Authors: Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic
Journal: J Clin Oncol Date: 2007-06-18 Impact factor: 44.544

Review 8. CpG island methylator phenotype in cancer.

Authors: Jean-Pierre Issa
Journal: Nat Rev Cancer Date: 2004-12 Impact factor: 60.716

9. Cellular differentiation, cytidine analogs and DNA methylation.

Authors: P A Jones; S M Taylor
Journal: Cell Date: 1980-05 Impact factor: 41.582

10. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.

Authors: Minoru Toyota; Hiromu Suzuki; Yasushi Sasaki; Reo Maruyama; Kohzoh Imai; Yasuhisa Shinomura; Takashi Tokino
Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701

1177 in total

A decade of exploring the cancer epigenome - biological and translational implications.

Review 1. The history of cancer epigenetics.

2. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line.

3. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

4. Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations.

5. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

6. DNMT3A mutations in acute myeloid leukemia.

7. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Review 8. CpG island methylator phenotype in cancer.

9. Cellular differentiation, cytidine analogs and DNA methylation.

10. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.

Review 1. Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition.

Review 2. Epigenetic plasticity and the hallmarks of cancer.

Review 3. Epigenetic research in cancer epidemiology: trends, opportunities, and challenges.

Review 4. Epigenetic effects of green tea polyphenols in cancer.

5. How has the study of the human placenta aided our understanding of partially methylated genes?

6. Inferring and modeling inheritance of differentially methylated changes across multiple generations.

7. Epigenetic abnormalities in cancer find a "home on the range".

8. Micro-editing mistake translates into a devastating brain tumor.

Review 9. Epigenetics and chromatin dynamics: a review and a paradigm for functional disorders.

10. Effect of estrogen receptor α binding on functional DNA methylation in breast cancer.